Drugs / T-Cell Therapy
T-Cell Therapy
also known as
E7 TCR · E7 TCR-T cells · Adoptive cell transfer · CTL 19 · KK-LC-1 TCR · KK-LC-1 TCR-T cells
Cell therapy targets HLA-DPB1 via depletion
Trials 10 · a red edge is where a trial was stopped
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02315118 ↗ |
| Known as | Adoptive cell transfer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01988077 ↗ |
| Known as | CTL 19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04180059 ↗ |
| Known as | E7 TCR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04411134 ↗ |
| Known as | E7 TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05639972 ↗ |
| Known as | KK-LC-1 TCR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05035407 ↗ |
| Known as | KK-LC-1 TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05483491 ↗ |
| Action | Deplete | “which mediates antibody-dependent cell cytotoxicity” NCT02315118 ↗ |
| Modality | Cell therapy | “Adoptive cell transfer combined with Ipilimumab” NCT01988077 ↗ |
| Route | Intravenous | “inject iv escalating dose” NCT04180059 ↗ |
| Target | HLA-DPB1 | “clone recognizing HLA-DPB1\*04:01” NCT04180059 ↗ |